5.360USD-2.19%Mkt Cap: 29.24M USDP/E: —Last update: 2026-05-26
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap29.24M USD
Enterprise Value8.23M USD
Revenue (TTM)-13.27K USD
Gross Profit1.60M USD
Net Income (TTM)-17.43M USD
Revenue/Share-0.0040 USD
Last Price5.360 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.11
PEG—
EV/EBITDA-0.59
EV/Revenue-620.38
P/S-2085.72
P/B0.93
EPS (TTM)-7.90
EPS (Forward)-2.43
52W Range
3.64510% of range21.40
52W High21.40 USD
52W Low3.645 USD
Profitability
Gross Margin0.00%
Oper. Margin110513.32%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-62.90%
ROA-27.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.68M USD
CapEx (TTM)—
FCF Margin78692.64%
FCF Yield-35.71%
Net Debt-19.44M USD
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.02
Current Ratio14.31
Quick Ratio13.91
Book Value/Sh5.523 USD
Cash/Share3.597 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateDec 24, 2024
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.40M
Float4.18M
Insiders7.70%
Institutions55.03%
Short Interest
Short Ratio1.0d
Short % Float0.86%
Short % Out.0.85%
Shares Short46.01K
Short (prev mo.)26.85K
Technical
SMA 504.776 (+12.2%)
SMA 2006.452 (-16.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)39.75K
Avg Vol (10d)53.36K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—